- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Keymed Biosciences Inc (2162)
Keymed Biosciences Inc stock price live, this page displays HK 2162 stock exchange data. View the 2162 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Keymed Biosciences Inc real time stock price chart below.
What Is the Keymed Biosciences Inc Stock Price Today?
The Keymed Biosciences Inc stock price today is 76.40.
What Is the Stock Symbol for Keymed Biosciences Inc?
The stock symbol for Keymed Biosciences Inc is "2162."
What Stock Exchange Does Keymed Biosciences Inc Trade On?
Keymed Biosciences Inc is listed and trades on the Hong Kong stock exchange.
Is Keymed Biosciences Inc a Good Stock to Buy?
Determining whether Keymed Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2162 quote. (ISIN: KYG5252B1023)
What Is the Keymed Biosciences Inc Stock Price Today?
The Keymed Biosciences Inc stock price today is 76.40.
What Is the Stock Symbol for Keymed Biosciences Inc?
The stock symbol for Keymed Biosciences Inc is "2162."
What Stock Exchange Does Keymed Biosciences Inc Trade On?
Keymed Biosciences Inc is listed and trades on the Hong Kong stock exchange.
Is Keymed Biosciences Inc a Good Stock to Buy?
Determining whether Keymed Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2162 quote. (ISIN: KYG5252B1023)
76.40
-3.10(-3.90%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
75.90
79.90
52 wk Range
44.66
89.75
2162 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
75.9079.90
52 wk Range
44.6689.75
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2162 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
103.96
Upside
+36.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
15 Buy
0 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 103.96
(+36.07% Upside)
Earnings
Latest Release
Sep 25, 2025
EPS / Forecast
-0.30 / --
Revenue / Forecast
498.75M / --
Compare 2162 to Peers and Sector
Metrics to compare | 2162 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2162PeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.9x | −14.8x | −0.4x | |
PEG Ratio | 0.07 | 0.06 | 0.00 | |
Price/Book | 5.0x | 5.3x | 2.6x | |
Price / LTM Sales | 24.0x | 11.1x | 3.0x | |
Upside (Analyst Target) | 31.1% | 34.1% | 49.7% | |
Fair Value Upside | Unlock | −4.7% | 6.8% | Unlock |
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study; and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial. It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma; CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia; CM383, an Aß protofibrils antibody in Phase Ib clinical study; and CM559, a N3pG Aß antibody in Phase I clinical study. In addition, the company is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study; CM326, a TSLP antibody; CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody; and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody. It has an out-licence agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Keymed Biosciences (2162) Stock Price Today?
The Keymed Biosciences stock price today is 76.40 HKD.
What Stock Exchange Does Keymed Biosciences Trade On?
Keymed Biosciences is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Keymed Biosciences?
The stock symbol for Keymed Biosciences is "2162."
What Is the Keymed Biosciences Market Cap?
As of today, Keymed Biosciences market cap is 23.42B HKD.
What Is Keymed Biosciences's Earnings Per Share (TTM)?
The Keymed Biosciences EPS (TTM) is 2.71.
From a Technical Analysis Perspective, Is 2162 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Keymed Biosciences Stock Split?
Keymed Biosciences has split 0 times.
How Many Employees Does Keymed Biosciences Have?
Keymed Biosciences has 1768 employees.
What is the current trading status of Keymed Biosciences (2162)?
As of Sep 09, 2026, Keymed Biosciences (2162) is trading at a price of 76.40 HKD, with a previous close of 79.50 HKD. The stock has fluctuated within a day range of 75.90 HKD to 79.90 HKD, while its 52-week range spans from 44.66 HKD to 89.75 HKD.
What Is Keymed Biosciences (2162) Price Target According to Analysts?
The average 12-month price target for Keymed Biosciences is 103.96 HKD, with a high estimate of 119.17806618 HKD and a low estimate of 90.37998363 HKD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +36.07% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.